Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Horwitz

Showing results (681-690 of 717) with videos related to

Pageof 72
Sort By:
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Non-Hodgkin's lymphomas, version 4.2014Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patientsRebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Diffuse Large B-Cell Lymphoma Version 1.2016Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2013
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remissionErica D Warlick, Kristjan Paulson, Ruta Brazauskas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.
American Journal of Hematology|June 13, 2025
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell LymphomaAlyssa Bouska, Weiwei Zhang, Sunandini Sharma, et al.
Pageof 72

Showing results (681-690 of 717) with videos related to

Sort By:
Pageof 72
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Non-Hodgkin's lymphomas, version 4.2014Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patientsRebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Diffuse Large B-Cell Lymphoma Version 1.2016Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.
Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2013
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remissionErica D Warlick, Kristjan Paulson, Ruta Brazauskas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.
American Journal of Hematology|June 13, 2025
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell LymphomaAlyssa Bouska, Weiwei Zhang, Sunandini Sharma, et al.
Pageof 72